New hope for breast cancer patients: experimental drug combo enters Mid-Stage trial
NCT ID NCT07666555
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a new drug called culmerciclib, combined with fulvestrant, works better than standard CDK4/6 inhibitors plus fulvestrant for people with HR-positive, HER2-negative breast cancer that has worsened after first-line hormone therapy. About 98 women aged 18 to 75 will take part. The study measures how long the cancer stays under control and how many patients respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
culmerciclib (a CDK2/4/6 inhibitor) combined with fulvestrant
What this could lead to
If successful, this could offer a new treatment option for people with HR-positive, HER2-negative breast cancer whose disease has progressed after initial hormone therapy.
What could go wrong
This is a mid-stage trial with only 98 participants, so results may not apply to everyone. The new drug may not be more effective or safer than existing CDK4/6 inhibitors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan Cancer Center
RECRUITINGShanghai, China